Table of Contents

company-logo

Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications in the United States. Its MultiTAA-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens and kill tumor cells expressing tumor-associated antigens. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, and various solid tumors; allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia; and off-the-shelf products in various indications. It is also developing TPIV100/110, a peptide-based immunotherapeutic vaccines for the treatment of breast and ovarian cancer cells; and TPIV200, which is in Phase 2 clinical trial for the treatment of breast and ovarian cancers. The company was founded in 1999 and is headquartered in Houston, Texas.

Marker Therapeutics Dividend Announcement

• Marker Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Marker Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Marker Therapeutics Dividend History

Marker Therapeutics Dividend Yield

Marker Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Marker Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Marker Therapeutics Financial Ratios

P/E ratio-3.08
PEG ratio-0.08
P/B ratio3.99
ROE-89.63%
Payout ratio0.00%
Current ratio3.15
Quick ratio3.15
Cash Ratio2.60

Marker Therapeutics Dividend FAQ

Does Marker Therapeutics stock pay dividends?
Marker Therapeutics does not currently pay dividends to its shareholders.
Has Marker Therapeutics ever paid a dividend?
No, Marker Therapeutics has no a history of paying dividends to its shareholders. Marker Therapeutics is not known for its dividend payments.
Why doesn't Marker Therapeutics pay dividends?
There are several potential reasons why Marker Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Marker Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Marker Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Marker Therapeutics a dividend aristocrat?
Marker Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Marker Therapeutics a dividend king?
Marker Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Marker Therapeutics a dividend stock?
No, Marker Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Marker Therapeutics stocks?
To buy Marker Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Marker Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.